Cargando…

Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy

OBJECTIVE: This study aimed to develop and validate a nomogram to predict the probability of prostate cancer (PCa) after transperineal prostate biopsy by combining patient clinical information and biomarkers. METHODS: First, we retrospectively collected the clinicopathologic data from 475 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Wenming, Xu, Yujie, Yang, Congcong, Cheng, Li, Yao, Peng, Fu, Shimin, Han, Jie, Zhuo, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751862/
https://www.ncbi.nlm.nih.gov/pubmed/36531011
http://dx.doi.org/10.3389/fonc.2022.1038177
_version_ 1784850576176054272
author Ren, Wenming
Xu, Yujie
Yang, Congcong
Cheng, Li
Yao, Peng
Fu, Shimin
Han, Jie
Zhuo, Dong
author_facet Ren, Wenming
Xu, Yujie
Yang, Congcong
Cheng, Li
Yao, Peng
Fu, Shimin
Han, Jie
Zhuo, Dong
author_sort Ren, Wenming
collection PubMed
description OBJECTIVE: This study aimed to develop and validate a nomogram to predict the probability of prostate cancer (PCa) after transperineal prostate biopsy by combining patient clinical information and biomarkers. METHODS: First, we retrospectively collected the clinicopathologic data from 475 patients who underwent prostate biopsy at our hospital between January 2019 to August 2021. Univariate and multivariate logistic regression analyses were used to select risk factors. Then, we established the nomogram prediction model based on the risk factors. The model performance was assessed by receiver operating characteristic (ROC) curves, calibration plots and the Hosmer–Lemeshow test. Decision curve analysis (DCA) was used to evaluate the net benefit of the model at different threshold probabilities. The model was validated in an independent cohort of 197 patients between September 2021 and June 2022. RESULTS: The univariate and multivariate logistic regression analyses based on the development cohort indicated that the model should include the following factors: age (OR = 1.056, p = 0.001), NEUT (OR = 0.787, p = 0.008), HPR (OR = 0.139, p < 0.001), free/total (f/T) PSA (OR = 0.013, p = 0.015), and PI-RADS (OR = 3.356, p < 0.001). The calibration curve revealed great agreement. The internal nomogram validation showed that the C-index was 0.851 (95% CI 0.809-0.894). Additionally, the AUC was 0.851 (95% CI 0.809-0.894), and the Hosmer–Lemeshow test result presented p = 0.143 > 0.05. Finally, according to decision curve analysis, the model was clinically beneficial. CONCLUSION: Herein, we provided a nomogram combining patients’ clinical data with biomarkers to help diagnose prostate cancers.
format Online
Article
Text
id pubmed-9751862
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97518622022-12-16 Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy Ren, Wenming Xu, Yujie Yang, Congcong Cheng, Li Yao, Peng Fu, Shimin Han, Jie Zhuo, Dong Front Oncol Oncology OBJECTIVE: This study aimed to develop and validate a nomogram to predict the probability of prostate cancer (PCa) after transperineal prostate biopsy by combining patient clinical information and biomarkers. METHODS: First, we retrospectively collected the clinicopathologic data from 475 patients who underwent prostate biopsy at our hospital between January 2019 to August 2021. Univariate and multivariate logistic regression analyses were used to select risk factors. Then, we established the nomogram prediction model based on the risk factors. The model performance was assessed by receiver operating characteristic (ROC) curves, calibration plots and the Hosmer–Lemeshow test. Decision curve analysis (DCA) was used to evaluate the net benefit of the model at different threshold probabilities. The model was validated in an independent cohort of 197 patients between September 2021 and June 2022. RESULTS: The univariate and multivariate logistic regression analyses based on the development cohort indicated that the model should include the following factors: age (OR = 1.056, p = 0.001), NEUT (OR = 0.787, p = 0.008), HPR (OR = 0.139, p < 0.001), free/total (f/T) PSA (OR = 0.013, p = 0.015), and PI-RADS (OR = 3.356, p < 0.001). The calibration curve revealed great agreement. The internal nomogram validation showed that the C-index was 0.851 (95% CI 0.809-0.894). Additionally, the AUC was 0.851 (95% CI 0.809-0.894), and the Hosmer–Lemeshow test result presented p = 0.143 > 0.05. Finally, according to decision curve analysis, the model was clinically beneficial. CONCLUSION: Herein, we provided a nomogram combining patients’ clinical data with biomarkers to help diagnose prostate cancers. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9751862/ /pubmed/36531011 http://dx.doi.org/10.3389/fonc.2022.1038177 Text en Copyright © 2022 Ren, Xu, Yang, Cheng, Yao, Fu, Han and Zhuo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ren, Wenming
Xu, Yujie
Yang, Congcong
Cheng, Li
Yao, Peng
Fu, Shimin
Han, Jie
Zhuo, Dong
Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
title Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
title_full Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
title_fullStr Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
title_full_unstemmed Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
title_short Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
title_sort development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751862/
https://www.ncbi.nlm.nih.gov/pubmed/36531011
http://dx.doi.org/10.3389/fonc.2022.1038177
work_keys_str_mv AT renwenming developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT xuyujie developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT yangcongcong developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT chengli developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT yaopeng developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT fushimin developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT hanjie developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy
AT zhuodong developmentandvalidationofapredictivemodelfordiagnosingprostatecanceraftertransperinealprostatebiopsy